Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia.
Sign Up to like & getrecommendations! Published in 2022 at "Internal medicine"
DOI: 10.2169/internalmedicine.0730-22
Abstract: Objective Anamorelin, a novel selective ghrelin receptor agonist, was approved in Japan for the treatment of cachexia in pancreatic cancer (PC), albeit with limited evidence. This study evaluated the efficacy and safety of anamorelin in… read more here.
Keywords: extent weight; loss group; weight loss; loss ... See more keywords